Menin inhibitor drugs

tional or clinical drug candidate Menin inhibitors (MIs) disrupt binding of Menin to its binding pocket in MLL1/2 and MLL1-FP, which reduces MLL1/2 and MLL1-FP binding to their targets

Revumenib, an orally administered cancer medicine known as a menin inhibitor drug revumenib in the AUGMENT-101 multicenter clinical

Orally bioavailable, investigational or clinical drug candidate Menin inhibitors (MIs) disrupt binding of Menin to its binding pocket in MLL1/2 and MLL1-FP, which reduces MLL1/2 and MLL1-FP

Five menin inhibitors are in clinical trials, but revumenib, which prevents menin–KMT2A binding, is the furthest along. The phase I/II AUGMENT-

Revumenib, a drug in a new class called menin inhibitors, was developed based on research conducted at MSK. It targets certain genetic changes

An orally bioavailable, small molecule inhibitor of menin, with potential antineoplastic activity. Upon oral administration, menin inhibitor DSP-5336 targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) and the formation of the menin-MLL complex.

protein interaction involving menin and KMT2A. By targeting and blocking the menin-KMT2A interaction, menin inhibitors can potentially stop or slow down the growth of these leukemia cells. How menin inhibitors work Side effects: Some menin inhibitors can cause QT interval prolongation (a heart rhythm issue) and differentiation syndrome (a severe

This work provides an attractive avenue for unexplored combinations of epigenetic inhibitors, such as menin inhibitors, with drugs targeting kinases. Methods. Cell lines and primary patient samples.

These novel MEN1 mutations decrease the affinity of the menin inhibitor interaction, preventing drug-induced displacement of the menin MLL1 complex from chromatin and thereby abrogating